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Melanoma cells replicate through
chemotherapy by reducing levels of key
homologous recombination protein RAD51
and increasing expression of translesion
synthesis DNA polymerase ζ
Liang Song1, Ewan M. McNeil1, Ann-Marie Ritchie1, Katy R. Astell1,2, Charlie Gourley1 and David W. Melton1*
Abstract
Background: The global incidence of melanoma has been increasing faster than any other form of cancer. New
therapies offer exciting prospects for improved survival, but the development of resistance is a major problem and
there remains a need for additional effective melanoma therapy. Platinum compounds, such as cisplatin, are the most
effective chemotherapeutics for a number of major cancers, but are ineffective on metastatic melanoma. They cause
monofunctional adducts and intrastrand crosslinks that are repaired by nucleotide excision repair, as well as the more
toxic interstrand crosslinks that are repaired by a combination of nuclease activity and homologous recombination.
Methods: We investigated the mechanism of melanoma resistance to cisplatin using a panel of melanoma and
control cell lines. Cisplatin-induced changes in levels of the key homologous recombination protein RAD51 and
compensatory changes in translesion synthesis DNA polymerases were identified by western blotting and qRT-PCR.
Flow cytometry, immunofluorescence and western blotting were used to compare the cell cycle and DNA damage
response and the induction of apoptosis in cisplatin-treated melanoma and control cells. Ectopic expression of a
tagged form of RAD51 and siRNA knockdown of translesion synthesis DNA polymerase zeta were used to investigate
the mechanism that allowed cisplatin-treated melanoma cells to continue to replicate.
Results: We have identified and characterised a novel DNA damage response mechanism in melanoma. Instead of
increasing levels of RAD51 on encountering cisplatin-induced interstrand crosslinks during replication, melanoma cells
shut down RAD51 synthesis and instead boost levels of translesion synthesis DNA polymerase zeta to allow replication
to proceed. This response also resulted in synthetic lethality to the PARP inhibitor olaparib.
Conclusions: This unusual DNA damage response may be a more appropriate strategy for an aggressive and rapidly
growing tumour like melanoma that enables it to better survive chemotherapy, but also results in increased sensitivity
of cultured melanoma cells to the PARP inhibitor olaparib.
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Background
Over the last 30 years the global incidence of melanoma
has increased faster than any other form of cancer.
Global incidence in 2012 was 232,000, and is predicted
to increase to 280,000 by 2020 [1]. It is now the second
most common cancer amongst young adults in the UK
[2]. Early surgical removal of primary tumours is an
effective treatment, but up to 20% of patients may go on
to develop metastatic disease, which has a very poor
prognosis. Standard chemotherapeutics, that have a
proven record of success against many different cancers,
are ineffective on metastatic melanoma. Five year
survival with the standard treatment, the alkylating agent
dacarbazine is <15% [3]. Global mortality in 2012 was
55,500, and is predicted to increase to 67,800 by 2020
[1]. The new BRAF inhibitors, combination therapies
and immunotherapies offer exciting prospects for
improved survival, but not all patients respond and the
development of resistance is a major problem [4, 5],
hence there remains a need for additional effective
melanoma therapy.
One possible approach is the use of PARP inhibitors,
such as olaparib. They are most effective as anticancer
agents in situations where the homologous recombin-
ation repair (HRR) pathway for the repair of dsDNA
breaks is defective. Olaparib causes PARP to be trapped
onto DNA repair intermediates, especially during base
excision repair. This may cause obstruction to replica-
tion forks that is normally resolved by BRCA-dependent
homologous recombination. If this pathway is non-
functional then apoptosis is triggered [6]. The paradigm
for this synthetic lethality is in BRCA-mutant ovarian
and breast cancers and it is to these cancers that PARP
inhibitors have initially been targeted [7–10]. A number
of genes in addition to BRCA1 and 2 are involved in the
HRR pathway and a mutation in any one of these could
also lead to synthetic lethality with olaparib. This realisa-
tion has triggered a search to identify other cancer
patients with a “BRCAness” phenotype that should also
respond to PARP inhibitor therapy. One biomarker
suggested to monitor the activity of the HRR pathway is
RAD51, the enzyme responsible for the key strand
exchange step in the process. In principle this synthetic
lethality approach should also be applicable to melan-
oma. However, one approach, combining olaparib with
dacarbazine, found no clinical advantage over dacarba-
zine alone [11].
Increased expression of many DNA repair genes has been
found in primary melanomas that went on to metastasize
compared to non-recurrent primaries [12–14]. We have
been investigating the possibility that alterations in DNA
repair gene expression could contribute to the extreme
resistance that melanoma shows to chemotherapy.
Platinum compounds, such as cisplatin, are the most
effective chemotherapeutics for a number of major cancers,
such as ovarian and lung. They cause monofunctional
adducts and intrastrand crosslinks that are repaired by the
nucleotide excision repair (NER) pathway, and also the
more toxic interstrand crosslinks (ICLs) that are repaired
by a combination of nuclease activity and HRR [15]. The
ERCC1-XPF endonuclease is required for both repair
pathways [16]. We have previously shown that ERCC1 and
XPF gene expression is elevated by exposure of melanoma
cells to cisplatin and that ERCC1 inactivation or inhibition
renders melanoma sensitive to cisplatin [17–19].
Here we identify and characterise a novel DNA
damage response mechanism in melanoma, involving in-
activation of the key HRR protein RAD51 and increased
translesion synthesis DNA polymerase activity, that
allows melanoma cells to continue to grow in the pres-
ence of cisplatin. We also test the hypothesis that this
response might also render melanoma susceptible to
synthetic lethality with olaparib.
Methods
Mammalian cells
Human melanoma cells A375, C32, G361, HBL and
WM115, and MRC5v1 SV40 transformed primary
human fibroblasts [20], all authenticated by short tan-
dem repeat profiling, were obtained from The European
Collection of Cell Cultures (Salisbury, UK). Early passage
established human ovarian cancer cell lines, PEO1 and
PEO4, were kindly provided by their isolator Dr. Simon
Langdon, University of Edinburgh, directly from frozen
stocks established soon after their original isolation [21].
All experiments were performed on cultures within 10
passages of their supply. Cells were maintained in
DMEM medium (41965; Life Technologies Ltd., Paisley,
UK), or RPMI 1640 medium (PEO1 and 4 only; 21875,
Life Technologies Ltd.), supplemented with 10% FCS,
Non-Essential Amino Acids (11140–035; Life Technologies
Ltd.), 1 mM Sodium Pyruvate, 2 mM L-glutamine and
Penicillin [100 U/ml] –Streptomycin (100 mg/ml) at 37 °C,
5% CO2.
Platinum response assays
A375 cells were plated at 55000 cells/well in 6-well
plates. Twenty-four hours later cells were transfected
using Lipofectamine 2000 as recommended by the
supplier (Life Technologies Ltd.). Plasmid pCMV5
FLAG-RAD51 (90 ng, supplied by MRC Protein
Phosphorylation and Ubiquitylation Unit, University of
Dundee, UK) was used/well to express equivalent levels
of FLAG-RAD51 to endogenous RAD51. In separate
transfections 40 pmol of ON-TARGETplus REV3L
(5980) siRNA SMARTpool/well, with ON-TARGETplus
Non-targeting Pool control siRNA (GE Dharmacon,
Lafayette, CO), was used to knockdown DNA Pol ζ. Four
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hours after transfection 1 μM cisplatin (Hospira UK
Ltd., Leamington Spa, UK) was added to some trans-
fected and non-transfected wells. Cells were har-
vested 24, 48 and 72 h later for cell number counts,
flow cytometry and protein lysates. Flow cytometry,
to determine the effect of cisplatin on cell cycle
status, was carried out by propidium iodide staining
as described [22].
Cell culture toxicity assays
A375 cells were plated at 500 cells per well directly into
96-well plates, containing an olaparib dilution series, in
the presence or absence of cisplatin. DMSO was
maintained at <0.75%. Plates were cultured for 5 days
and cell growth was quantified using a Sulphorhodamine
B (SRB) assay [23].
Western blotting
Protein extraction was carried out on ice using RIPA
buffer (25 mM Tris-HCl pH 7.2, 150 mM NaCl, 1%
Triton X-100, 1% deoxycholate, 1 mM EDTA, 20 mM
NaF, 100 μM orthovanadate), with Roche complete pro-
tease inhibitor cocktail (Roche Products Ltd., Welwyn
Garden City, UK). Primary antibodies: ERCC1, rabbit
polyclonal FL-297 at 1:1000 dilution (Santa Cruz
Biotechnology Inc., Dallas, TX); XPF, mouse monoclonal
Ab-5 at 1:1000 (Thermo Fisher Scientific UK Ltd.,
Loughborough, UK); XPA, rabbit polyclonal NB100–
92124 at 1:1000 (Novus Biologicals LLC., Littleton, CO);
RAD51, rabbit polyclonal PC130 at 1:1000 (Merck
Millipore Corporation, Darmstadt, Germany); DNA pol
ζ, goat polyclonal sc-5939 at 1:100 (Santa Cruz Biotech-
nology Inc.); DNA pol η, rabbit polyclonal ab180703 at
1:200 (Abcam, Cambridge, UK); FLAG tag, mouse
monoclonal F1804 at 1:1000 (Sigma-Aldrich, Poole, UK);
cleaved Caspase-3, rabbit polyclonal #9661 at 1:1000
(Cell Signaling Technology, Danvers, MA); β-actin,
mouse monoclonal A1978 at 1:10,000 (Sigma-Aldrich,
Poole, UK), Lamin A/C, rabbit polyclonal #2032 at
1:1000 (Cell Signaling Technology). Secondary anti-
bodies used following the primary antibody incubations:
HRP-conjugated forms of goat anti-rabbit (P0448 at
1:3000, DAKO UK Ltd., Ely, UK), rabbit anti-goat
(P0449 1:4000, DAKO) and rabbit anti-mouse (P0260
1:2000, DAKO). Western blotting was performed as
described [18].
Quantitative RT-PCR
Total RNA was extracted and quantitative RT-PCR reac-
tions were carried out as described [17]. The primer
pairs used were: q-PCR TaqMan RAD51 primer pair
Hs00153418, q-PCR TaqMan beta-actin primer pair
4352935E.
Determination of RAD51 DNA repair foci
Cells were seeded onto coverslips in wells of a 6-well
plate containing 2 ml of medium and incubated at 37 °C
for 24 h to allow them to adhere. They were then
incubated for a further 24 h in control medium or
medium with 6 μM cisplatin before fixing in 4% parafor-
maldehyde at 37 °C for 15 min. Cells were then washed
3 times with PBS for 5 min with gentle agitation,
permeabilised with methanol:acetone (1:1) at −20 °C for
5 min, followed by another 3 PBS washes and stored in
PBS at 4 °C until required. For RAD51 immunofluores-
cence, after 60 min blocking with 10% donkey serum,
rabbit polyclonal antibody PC130 (1:400 dilution) was
used overnight at 4 °C. Following 3 PBS washes,
coverslips were incubated with fluorochrome-conjugated
secondary antibody diluted 1:1000 for 60 min at room
temperature (Alexa Fluor® 488 AffiniPure Donkey Anti-
Rabbit IgG (H + L) 711–545-152; Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA). Coverslips
were then washed and dried overnight in the dark before
being mounted in VECTASHIELD Mounting Medium
with DAPI (H-1200, VECTOR Laboratories Ltd.,
Peterborough, UK). Hardware control, immunofluores-
cence image capture and analysis were performed using
Volocity 3D image analysis software (PerkinElmer Inc.,
Waltham, MA).
Results
Decreased RAD51 levels in A375 melanoma cells after
cisplatin treatment
When A375 human melanoma cells were treated with
6 μM cisplatin for 48 h, an increase in the level of three
NER proteins, ERCC1, XPF and XPA, was seen. How-
ever, when the same samples were probed for RAD51,
we observed a dramatic and unexpected decrease in the
level of this key HR protein that is needed for the
removal of cisplatin-induced ICLs by HRR (Fig. 1a). We
then investigated the time course and concentration-
dependence of this RAD51 response to cisplatin. After
48 h of treatment the decrease was detectable at 1 μM
cisplatin and, by 72 h, the level of RAD51 was much re-
duced at the lowest cisplatin concentration used, 0.3 μM
(Fig. 1b). After 72 h of treatment at the highest cisplatin
concentrations (3 and 6 μM), RAD51 protein was barely
detectable by western blot.
Decreased RAD51 levels after cisplatin treatment is
particular to melanoma cells
To investigate whether this unexpected RAD51 response
to cisplatin was peculiar to A375 cells, or was instead a
more general feature of melanoma, we assembled a
panel of metastatic (A375, G361, HBL) and primary
(C32 and WM115) human melanoma cell lines for
further study. For comparison we also included an
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immortalised human fibroblast line (MRC5v1) and two
human high grade serous ovarian cancer cell lines. PEO1
was isolated from a patient with a platinum-sensitive
cancer, PEO4 was isolated from the same patient after
the cancer became platinum-resistant. PEO1 is a BRCA2
mutant, PEO4 is a BRCA2 revertant. Cultures were
treated with 0.3, 1 and 3 μM cisplatin for 24, 48 and
72 h. Although there was some apoptosis evident in
dishes treated with 3 μM cisplatin for 72 h, cultures
from all cell lines remained alive and healthy for the
duration of this experiment. Cell cycle analysis and
apoptosis in cisplatin-treated cultures are described later
in the Results section. Representative western blots for
RAD51 and the β-actin loading control are shown in
Additional file 1: Figure S1 and histograms of RAD51
protein expression relative to β-actin and normalised to
the level in untreated control cultures are shown in
Fig. 2. Although there was some heterogeneity in the
timing of the RAD51 response of the melanoma cell
lines, with C32 in particular showing an initial 2-fold
increase at 24 h with the higher cisplatin concentrations,
all showed the same major reduction in RAD51 levels
seen previously in A375 after 72 h of 1 and 3 μM
cisplatin treatment (>65% reduction at 3 μM). The situ-
ation was very different in the non-melanoma lines at
the same time point, where none showed any RAD51 re-
duction and, for MRC5v1 and PEO4, increased RAD51
protein expression after 72 h of 1 and 3 μM cisplatin
treatment was evident. A similar increase in RAD51
levels after cisplatin treatment has been reported in lung
cancer cell lines [24].
No increase in RAD51 DNA repair foci in the short term
response of melanoma cells to cisplatin
RAD51 protein levels in A375 melanoma cells had
already reduced by 50% after 24 h of 3 μM cisplatin
treatment, with no equivalent reduction seen in non-
melanoma cells (Fig. 2). To investigate the DNA repair
response during this period we used immunofluores-
cence to investigate RAD51 DNA repair foci following
24 h of 6 μM cisplatin treatment in A375 melanoma,
PEO4 ovarian cancer cells and MRC5v1 immortalised
fibroblasts. The results are shown in Fig. 3 and represen-
tative images are in Additional file 1: Figure S2. MRC5v1
showed the classic repair response to cisplatin-induced
DNA damage, with a significant 4-fold increase (P =
<0.001 by Student’s t test) in the number of RAD51 foci
in cisplatin-treated cells compared to controls. The
BRCA2 revertant ovarian cancer cell line, PEO4, showed
a smaller but still significant (P = 0.001) 2-fold increase
in RAD51 foci after cisplatin treatment. The response of
A375 melanoma cells was very different with no signifi-
cant (P = 0.44) increase in RAD51 foci after cisplatin.
We conclude that the reduction in RAD51 levels in
A375 melanoma cells on cisplatin treatment is accom-
panied by a different DNA repair response to that seen
in the non-melanoma cells.
The fall in RAD51 protein in cisplatin-treated melanoma
cells is due to reduced RAD51 mRNA levels
To investigate the basis for the reduced RAD51 levels
after cisplatin treatment of melanoma cells, cultures of
A375, C32, G361, PEO4 and MRC5v1 cells were treated
with 3 μM cisplatin for 24, 48 and 72 h before RNA was
extracted and RAD51 mRNA levels were determined by
quantitative RT-PCR. Levels of RAD51 mRNA, relative
to β-actin in cisplatin-treated cultures and normalised to
the level in control cultures, are shown in Fig. 4. RAD51
mRNA levels in A375 were already reduced to 32% of
the untreated control after 24 h of cisplatin treatment,
with levels falling further with prolonged treatment,
down to 11% at 72 h. RAD51 mRNA levels also fell pro-
gressively with cisplatin treatment in the other two mel-
anoma cell lines examined, C32 and G361, albeit not to
the same extent as seen in A375. No similar reduction
in RAD51 mRNA levels was seen in PEO4 and MRC5v1,
instead levels were unaltered over the time course of cis-
platin treatment in MRC5v1 and rose by up to 3.8-fold
in PEO4. We next investigated whether increased prote-
olysis by either of the two main pathways was also con-
tributing to the cisplatin-induced reduction in RAD51
a
b
Fig. 1 Reduced RAD51 levels in melanoma cells after cisplatin treatment.
a Levels of Nucleotide Excision Repair proteins increase after cisplatin
treatment of A375 melanoma cells, while levels of RAD51 decrease
dramatically. Total protein extracts from untreated A375 human melanoma
cells and cells treated with 6 μM cisplatin (CDDP) for 48 h were western
blotted for the NER proteins, ERCC1 (33 kDa), XPF (104 kDa) and XPA
(40 kDa) and the homologous recombination protein, RAD51 (37 kDa).
β-actin (42 kDa) served as the loading control. b Cisplatin concentration-
and treatment time-dependent decrease in RAD51 levels in A375
melanoma cells. Total protein extracts from untreated A375 human
melanoma cells and cells treated with CDDP concentrations ranging from
0.3 to 6 μM for 48 and 72 h were western blotted for RAD51. β-actin
served as the loading control. The positions of molecular weight markers
(in kDa) adjacent to proteins of interest are shown
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levels in melanoma. Proteasome-dependent proteolysis was
inhibited with MG132 or bortezomib, while bafilomycin A1
was used to block the lysosome-dependent pathway. A375
and C32 cells treated with 3 μM cisplatin for 72 h were also
exposed in combination with MG132 (1 μM) (Additional
file 1: Figure S3A). There was no evidence that blocking
proteasome-mediated proteolysis could reverse the
cisplatin-induced reduction of RAD51 levels. As a positive
control for inhibition of proteasomal degradation, A375
cells treated with MG132 showed an ~2-fold increase over
Fig. 2 The reduction in RAD51 levels after cisplatin treatment in melanoma cells is not seen in other cell types. Graphs show the expression of
RAD51, determined by western blotting, in five human melanoma cell lines (A375, C32, G361, HBL and WM115), two human ovarian cancer cell
lines (PEO1 and PEO4) and the immortalised human fibroblast line, MRC5v1. Cells were untreated, or treated with 0.3, 1 or 3 μM cisplatin for 24,
48 or 72 h. RAD51 expression is plotted relative to β-actin and normalised to the level in untreated cells. Results are the means from two separate
determinations. Representative western blots themselves are shown in Additional file 1: Figure S1
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control cells in levels of the nucleotide excision repair
protein ERCC1 (Additional file 1: Figure S3B), which
we have previously shown to be degraded by the poly-
ubiquitination-dependent proteasome pathway [25]. Simi-
larly, treatment of A375 cells with proteasome inhibitor
bortezomib (10 nM) was unable to reverse the cisplatin-
induced reduction in RAD51 levels (Additional file 1: Fig-
ure S3C). Lysosome-dependent proteolysis inhibitor bafi-
lomycin A1 (1 μM) also had no effect on RAD51 levels in
cisplatin treated G361 cells (Additional file 1: Figure S3D).
Although there were some discrepancies between RAD51
protein and mRNA levels, we conclude that the cisplatin-
induced reduction in RAD51 levels in melanoma cells is
due to reduced RAD51 mRNA levels rather than in-
creased proteolysis.
The cisplatin-induced reduction in RAD51 induced synthetic
lethality to olaparib in A375 melanoma cells
The unusual RAD51 response to cisplatin in melanoma
cells led us to hypothesise that we could induce synthetic
Fig. 3 RAD51 DNA repair foci are not induced by short term cisplatin treatment of melanoma cells. A375 melanoma, MRC5v1 immortalised fibroblasts
and PEO4 ovarian cancer cells growing on coverslips were treated for 24 h with 6 μM cisplatin and the number of RAD51 foci in treated and control
cultures was determined by RAD51 immunofluorescence of fixed cells. Graph shows the mean number of RAD51 foci per nucleus (±SEM) for treated and
control cultures. Between 40 and 60 nuclei were scored for each cell type and treatment. Representative images are shown in Additional file 1: Figure S2
Fig. 4 Reduced RAD51 mRNA levels in melanoma cells after cisplatin treatment. A375, C32, G361 melanoma cells, PEO4 ovarian cancer cells and
MRC5v1 fibroblasts were treated with 3 μM cisplatin for 24, 48 or 72 h. RNA was extracted and RAD51 mRNA levels were determined by quantitative
RT-PCR. RAD51 mRNA expression (±SEM, n = 3) is shown relative to β-actin and normalised to the level in untreated control (Cont.) cells
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lethality and so render melanoma sensitive to PARP inhib-
itors by simultaneous exposure to cisplatin. The result of
an A375 growth assay in a dilution series of olaparib in
the presence and absence of 0.5 μM cisplatin is shown in
Fig. 5. This cisplatin concentration is well below the IC50
value (1.04 μM) in the 5-day growth assay that we have re-
ported previously [19]. When the toxicity of cisplatin
alone was corrected for, we found that cisplatin caused a
modest 5-fold enhanced sensitivity to olaparib (olaparib
IC50 2.56 μM, olaparib plus cisplatin IC50 0.45 μM, P <
0.0001). Our other melanoma lines were not tested for
induced synthetic lethality to olaparib.
Melanoma cells show only a weak G2 arrest after cisplatin
treatment
We next began to consider how the unusual RAD51 re-
sponse of melanoma cells to cisplatin might be connected
to the resistance of melanoma to chemotherapy. A strong
G2 arrest, triggered by DNA replication arrest at inter-
strand crosslinks, is the normal response to cisplatin. The
cell cycle profiles of A375 melanoma, MRC5v1 fibroblasts
and platinum sensitive, PEO1, and resistant, PEO4,
ovarian cancer cells were determined in response to 0.3
and 1 μM cisplatin treatment for 24 and 48 h (Additional
file 1: Figure S4).The A375 profile was unaffected by
0.3 μM cisplatin, while at 1 μM there was a weak accumu-
lation of cells in G2 at 24 h, which had resolved by 48 h.
PEO1 showed an accumulation of cells in G2 at the lowest
cisplatin concentration, while PEO1, PEO4 and MRC5v1
showed strong G2 arrests at 1 μM cisplatin.
The RAD51 response of melanoma cells to cisplatin is a
specific transcriptional response resulting in improved
survival and growth
Next we investigated the significance and specificity of
the RAD51 response of melanoma cells to cisplatin by
expressing an N-terminal FLAG-tagged version of
RAD51, under vector rather than endogenous RAD51
promoter control, at levels equivalent to those of the
endogenous RAD51 protein. This tag has been used
extensively and is considered unlikely to affect the intra-
cellular location, stability and function of the tagged
protein [26]. If the RAD51 response was merely a non-
specific consequence of cisplatin treatment, for instance
as a result of apoptosis-induced proteolysis, then both
endogenous and FLAG-RAD51 proteins would be
expected to respond in the same way. This was not what
we observed (Fig. 6a). Endogenous RAD51 protein
showed the expected dramatic reduction over the 72 h
exposure to 1 μM cisplatin, while expression of FLAG-
RAD51 was essentially unaffected, thus indicating the
transcriptional specificity of the RAD51 response to
cisplatin.
When untreated control A375 wells were harvested at
the same time as wells treated for 72 h with 1 μM cis-
platin, the mean cell number in control wells had in-
creased 55-fold since plating. Untreated FLAG-RAD51-
expressing cells showed slower growth, with a 20-fold
increase in cell number over the same period and a
moderately elevated level of apoptosis (2.5% compared
to 0.7% for control cells, Fig. 6d). The mean cell number
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Fig. 5 Cisplatin enhances the sensitivity of melanoma cells to PARP inhibitor olaparib. Five-day SRB growth assay on A375 melanoma cells in
96-well plates showing enhanced sensitivity to olaparib in the presence of 0.5 μM cisplatin. This cisplatin concentration is well below the IC50
value. In order to correct for the toxicity of cisplatin alone, for each curve growth is expressed as the percentage of the non-olaparib-treated
control. Values plotted are mean % growth (±SEM) from three independent experiments
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of 1 μM cisplatin-treated cultures was 73 ± 2% of the
untreated control, while the mean cell number of the
cisplatin-treated cultures expressing FLAG-RAD51
was significantly less (P = 0.01 by Student’s t test), at only
47 ± 3% of the untreated FLAG-RAD51-expressing
control (Fig. 6b). Activation (cleavage) of caspase-3 is one
of the key early steps in apoptosis. Wells harvested after
48 h were also western blotted with an antibody specific
for the cleaved forms of caspase-3 (Fig. 6c). Although
cleaved caspase-3 (17 and 19 kDa fragments) were present
a
b
d
c
Fig. 6 Expression of FLAG-tagged RAD51 adversely affects the response of melanoma cells to cisplatin. a No cisplatin-induced reduction in levels
of FLAG-RAD51. Western blots from control A375 cells, cells transfected to express FLAG-RAD51 at levels equivalent to endogenous RAD51 and cells of
both types treated with 1 μM cisplatin for 24, 48 or 72 h. The blot was probed sequentially for RAD51 (RAD51 37 kDa, FLAG-RAD51 38.2 kDa), the FLAG
tag, and β-actin (42 kDa). b Reduced growth in cisplatin-treated cultures expressing FLAG-RAD51. The table shows the mean cell growth (±SEM, n = 4)
of wells after 72 h of 1 μM cisplatin treatment for non-transfected A375 cells expressed as a percentage of the untreated control, and for FLAG-RAD51
transfected A375 cells expressed as a percentage of the non-cisplatin-treated FLAG-RAD51 transfection control. The P value for Student’s paired t test,
comparing the effect of cisplatin on growth of normal and FLAG-RAD51-expressing cells is also shown. c Increased early apoptosis in cisplatin-treated
A375 cultures expressing FLAG-RAD51. Cultures treated as in (a) and western blotted for activated caspase-3 and β-actin after 48 h of 1 μM cisplatin
treatment. Note the highest levels of cleaved caspase-3 (at 17 and 19 kDa) in the sample transfected with FLAG-RAD51 and treated with cisplatin.
d Increased apoptosis in cisplatin-treated A375 cells expressing FLAG-RAD51. Cultures treated as in (a) after 72 h of 1 μM cisplatin. A representative flow
cytometry profile for each culture condition is shown, with the percentage of cells with subG1 (apoptotic), G1, S and G2/M DNA contents indicated
across the top of each profile. Note the highest level of subG1 (apoptotic) material in the cisplatin-treated FLAG-RAD51-expressing cells. The table
below shows the mean level of apoptosis (±SEM, n = 4) in wells after 72 h of cisplatin treatment. The P values for Student’s paired t test, comparing
the level of apoptosis between cisplatin-treated and untreated control wells, and between cisplatin-treated FLAG-RAD51-expressing wells and
untreated FLAG-RAD51-expressing wells are also shown
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in untreated FLAG-RAD51-expressing cells, the highest
levels were found in cisplatin-treated FLAG-RAD51-
expressing cells, where the cleaved caspase-3/ β-actin ratio
was 2.5-fold higher than the non-cisplatin-treated FLAG-
RAD51-expressing control. Representative cell cycle
profiles of control, cisplatin-treated, FLAG-RAD51-
expressing, and cisplatin-treated FLAG-RAD51-expressing
cultures after 72 h are shown in Fig. 6d. The small increase
in the percentage of cells with sub-G1 DNA content (apop-
totic) between cisplatin-treated and control cultures was
not significant, but the 5-fold increase in apoptosis between
cisplatin-treated FLAG-RAD51-expressing and untreated
FLAG-RAD51-expressing controls was significant (P = 0.01
by Student’s t test, n = 4). We conclude that the novel
RAD51 transcriptional response to cisplatin in melanoma
cells results in improved survival and growth over the time
course of our assay compared to melanoma cells also
expressing near endogenous levels of RAD51, but under
ectopic promoter control.
Melanoma cells respond to cisplatin with elevated levels
of translesion synthesis DNA polymerase zeta resulting in
improved survival and growth
How are melanoma cells able to continue to cycle in the
presence of 1 μM cisplatin? We have shown previously
[17], and again here, that levels of some NER proteins
are elevated in response to cisplatin. This could make
melanoma cells better able to repair cisplatin-induced
bulky adducts and intrastrand crosslinks using NER. In-
creased levels of ERCC1-XPF endonuclease activity
could also facilitate increased repair of cisplatin-induced
ICLs by HRR during S phase, but melanoma cells show
strong transcriptional downregulation of the key HRR
protein RAD51 in response to cisplatin? Translesion
synthesis (TLS) DNA polymerases are able to insert
bases on a damaged template to allow replication to
proceed. Since two such polymerases, DNA pol ζ (zeta)
and DNA pol η (eta), have been implicated in cisplatin
bypass [27, 28], we decided to investigate whether the
novel RAD51 response of melanoma to cisplatin also in-
volved altered expression of these two TLS polymerases.
DNA Pol ζ proved a difficult target to detect by western
blotting, with the large catalytic subunit (REV3L) at
353 kDa and a very limited choice of antibodies avail-
able. The specificity of the antibody used was confirmed
by transfection of A375 cells with siRNA to the REV3L
subunit (Additional file 1: Figure S5A). Detection of
DNA Pol η (78 kDa) was more routine (Additional file 1:
Figure S5B). Levels of DNA pol ζ increased in melanoma
lines (A375, C32 and G361) in the 3 days following ex-
posure to 3 μM cisplatin, but no increase occurred in
MRC5v1 fibroblasts and PEO4 ovarian cancer cells. The
largest increases (> 8-fold) were seen in A375 and C32
(see Fig. 7a for expression histograms and Additional
file 1: Figure S6A for representative blots). All cell lines
showed a small increase in DNA pol η expression (up to
2-fold) after cisplatin treatment, but this was not
melanoma-specific (Fig. 7b and Additional file 1: Figure
S6B). The remaining two melanoma lines (HBL and
WM115 were not assayed for DNA polymerase levels.
To investigate the significance of increased DNA pol ζ
levels in the response of A375 melanoma cells to cis-
platin, we used siRNA to the catalytic subunit REV3L to
knockdown DNA pol ζ and studied the effect on
cisplatin treatment (Fig. 7c). The mean cell number of
untreated control cultures increased 51-fold after 72 h.
The mean cell number of 1 μM cisplatin-treated cultures
was 67 ± 4% of the untreated control, and the mean cell
number of the cisplatin-treated cultures transfected with
scrambled siRNA was 48 ± 3% of the untreated control.
While the mean cell number of the cisplatin-treated
cultures transfected with DNA pol ζ siRNA was only 23 ±
1% of the untreated control, significantly 2-fold less than
the scrambled siRNA control (P = 0.01, n = 4). Representa-
tive cell cycle profiles of control, cisplatin-treated, and
cisplatin-treated cultures transfected with scrambled
siRNA or DNA pol ζ siRNA after 72 h are shown in
Fig. 7d. This time, compared to Fig. 6d, the small increase
in the percentage of cells with sub-G1 DNA content
(apoptotic) between cisplatin-treated and control cultures
was just significant (P = 0.04 by Student’s t test, n = 4).
However, the >2-fold increase in apoptosis between
cisplatin-treated DNA pol ζ siRNA-transfected and scram-
bled siRNA-transfected control wells was highly signifi-
cant (P = 0.007 by Student’s t test, n = 4). We conclude
that the increase in DNA pol ζ constitutes an important
part of the response to cisplatin in melanoma cells, result-
ing in improved survival and growth.
Discussion
Cisplatin-induced DNA damage is repaired by a combin-
ation of nucleotide excision repair (NER) and homologous
recombination repair (HRR). Standard chemotherapeutics,
such as cisplatin, are ineffective on metastatic melanoma
and we, and others, have shown that levels of a number of
NER proteins in melanoma cells are elevated in response
to cisplatin: ERCC1 and XPF [17], XPC and DDB2 [29],
XPA (this publication). Such increases in DNA repair pro-
teins likely contribute to the resistance of melanoma to
chemotherapy. However, when we examined the key HRR
protein, RAD51, we found that levels unexpectedly
decreased by at least 65% in all five melanoma cell lines
examined over a 3-day exposure to cisplatin, while levels
in an ovarian cancer and a fibroblast cell line increased
over the same period, as reported previously for lung
cancer cell lines [24]. The RAD51 response of the
melanoma lines was seen across a range of cisplatin con-
centrations up to 3 μM, which is cytotoxic for all
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melanoma and non-melanoma cell lines studied. The non-
melanoma lines showed no reduction in RAD51 levels,
even at the highest cisplatin concentration, showing that
the difference in the RAD51 response of melanoma and
non-melanoma lines to cisplatin is not simply a dose effect.
The RAD51 response of melanoma cells to cisplatin
could have been due to decreased synthesis, or increased
proteolysis, possibly simply as a consequence of cisplatin-
induced apoptosis. Estimates of the half-life of RAD51
protein range from 5.5 to ~24 h in primary fibroblast and
cancer cell lines, with no clear difference between cell
types [30, 31]. We found no evidence for increased
RAD51 proteolysis in cisplatin-treated cells via either of
the two main pathways (proteasome and lysosome). In-
stead, decreased levels of RAD51 mRNA largely explained
the reduction in RAD51 protein levels, suggesting that the
RAD51 response to cisplatin most likely occurs at the
transcriptional level. Evidence for the transcriptional spe-
cificity of this response was enhanced when a FLAG-
tagged version of RAD51, expressed in melanoma cells at
near endogenous levels, but under foreign promoter con-
trol, failed to show the cisplatin-induced reduction.
a
c
d
b
Fig. 7 Increased levels of translesion synthesis DNA Polymerase zeta in melanoma cells improves their response to cisplatin. a and b Increased
levels of DNA Polymerase zeta, but not DNA Polymerase eta after cisplatin treatment. Melanoma cell lines (A375, C32, G361), ovarian cancer cell
line, PEO4, and immortalised fibroblast line, MRC5v1, were untreated, or treated with 3 μM cisplatin for 24, 48 or 72 h and western blotted for
translesion synthesis DNA Polymerases. a DNA Pol ζ. b DNA Pol η. Graphs shows the expression relative to β-actin and normalised to the level in
untreated cells. Results are the means from two separate determinations. Representative western blots themselves are shown in Additional file 1:
Figure S6. c Reduced growth in cisplatin-treated cultures following siRNA knockdown of DNA Polymerase zeta. The table shows the mean cell
growth (±SEM, n = 4) of wells after 72 h of 1 μM cisplatin treatment for non-transfected A375 cells and cells transfected with DNA Polymerase
zeta siRNA or scrambled control siRNA, expressed as a percentage of the untreated control. The P value for Student’s paired t test, comparing the
effect of DNA Polymerase zeta siRNA or scrambled control siRNA transfection on cell growth of cisplatin-treated wells is also shown. d Increased
apoptosis in cisplatin-treated DNA Pol ζ siRNA-transfected A375 cells. Cultures treated as in (c) after 72 h of 1 μM cisplatin. A representative flow
cytometry profile for each culture condition is shown, with the percentage of cells with subG1 (apoptotic), G1, S and G2/M DNA contents indi-
cated across the top of each profile. Note the increased level of subG1 (apoptotic) material in the cisplatin-treated DNA Pol ζ siRNA-transfected
cells. The table below shows the mean level of apoptosis (±SEM, n = 4) in wells after 72 h of cisplatin treatment. The P values for Student’s paired
t test, comparing the level of apoptosis between cisplatin-treated and untreated control wells, and between cisplatin-treated DNA Pol ζ siRNA-
transfected wells and cisplatin-treated scrambled control siRNA-transfected wells are also shown
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RAD51 is overexpressed in the majority of human
cancers [32]. Oncoproteins, such as activated Ras and
SV40 T antigen, stimulate the RAD51 promoter and
RAD51 expression is positively regulated by the EGR1
transcription factor [32], while p53, which is mutated or
functionally inactivated in the majority of cancers, binds
to and represses the RAD51 promoter [33]. Transcrip-
tion factor AP2 also binds to a site in the RAD51
promoter to repress transcription in a p53-dependent
manner [34]. The E2F family of transcription factors
complex with and are activated by hypophosphorylated
forms of the Rb protein and other repressive pocket
proteins, such as p130. E2F4/p130 complexes bind to a
single site in the RAD51 promoter to repress transcrip-
tion [35], while E2F1 binds to the same site to activate
the promoter [36]. A variety of treatments, acting via
some of these transcription factors, have previously been
shown to repress RAD51 transcription: hypoxia [35];
methotrexate [37]; inhibition of PARP [38], HDACs [36],
and tyrosine kinases such as Gleevec [39]. The
melanoma-specific effect of cisplatin on RAD51 expres-
sion could also be mediated by one or more of the same
transcription factors. In this regard we have previously
shown that cisplatin regulates the MAPK pathway to in-
duce increased expression of DNA repair gene ERCC1
and increase melanoma chemoresistance [17].
Flow cytometry revealed the ability of melanoma cells
to continue cycling in the presence of 1 μM cisplatin. In
A375 melanoma cells there was a weak G2 arrest at 24 h
which had resolved by 48 h, while platinum sensitive
(PEO1), resistant (PEO4) ovarian cancer cells and
MRC5v1 fibroblasts all showed strong and persistent G2
arrests at 1 μM cisplatin. The failure of the majority of
melanoma cell lines tested to show a G2 arrest following
UV-irradiation has been reported previously [40].
How are melanoma cells able to continue to cycle in the
presence of cisplatin-induced interstrand crosslinks
(ICLs)? Our hypothesis, that the unexpected cisplatin-
induced RAD51 reduction that we observed was
important for this ability, was supported by expressing a
FLAG-tagged version of RAD51 at endogenous levels
under foreign promoter control. Levels of FLAG-RAD51
remained stable after cisplatin treatment, with cells
expressing FLAG-RAD51 showing significantly reduced
growth and increased apoptosis compared to cisplatin-
treated control cultures during the three day time course
of our assay. This conclusion was reached after correcting
for the small negative effect that FLAG-RAD51 expression
alone had on the growth of untreated cells. The use of an
alternative inducible version of tagged RAD51, also ex-
pressing at endogenous levels, would avoid this
complication.
Many of the helix-distorting ICLs caused by cisplatin
are removed during G1 by a combination of the
unhooking action of endonucleases, such as ERCC1-
XPF, and translesion DNA synthesis (reviewed in [15]).
This activity and the removal of cisplatin-induced intras-
trand cross-links and monoadducts by NER could ex-
plain the increased levels of NER proteins we observed
in cisplatin-treated melanoma cells. Specialised transle-
sion synthesis (TLS) DNA polymerases provide a mech-
anism to allow cells to continue replication on a
damaged DNA template, albeit at the expense of an in-
creased mutation rate [26]. Complete bypass of cisplatin
lesions requires two cooperating TLS DNA polymerases:
DNA Pol η to insert dCTP opposite the 3′ guanine of
an intrastrand crosslink (and presumably also opposite
the G residue of an interstrand crosslink unhooked by
ERCC1-XPF, or other endonuclease action), and DNA
Pol ζ, which is more processive than DNA Pol η, for
subsequent primer extension [27]. The majority of ICLs
persisting into replication and encountered by replica-
tion forks are bypassed through a FANCM-dependent
replication-traverse pathway to permit DNA synthesis to
continue on the other side of the lesion [41]. The
unrepaired ICLs are later dealt with by a post-replication
repair process, likely to involve combined endonuclease
action and translesion synthesis. While the minority of
ICLs that block replication fork progression are unhooked
by endonuclease action, generating a double strand break.
Then, in a more protracted process, a combination of
translesion synthesis, followed by RAD51-dependent
HRR, enables replication to proceed [42].
In melanoma, as well as a range of other cancer and
normal cell lines, increased Pol η expression was in-
duced by exposure to chloroethyl nitrosoureas [43]. Like
cisplatin, these agents generate ICLs, but these are be-
tween adjacent G and C residues, rather than adjacent
Gs with platinum compounds. The Pol η transcriptional
response was p53-dependent and increased levels of Pol
η conferred increased resistance to the chloroethyl nitro-
soureas. Although DNA Pol η also contributes to the
tolerance of cisplatin adducts [26], DNA Pol ζ was found
to be the major determinant in mediating platinum
resistance in HeLa cells [44]. A 2-fold increase in DNA
Pol ζ mRNA levels has been reported previously in a
cisplatin-treated clonal derivative of the near-diploid,
immortal human fibroblast line MSU-1.1 [45]. siRNA
knockdown of the REV3L catalytic subunit of DNA
Pol ζ in HeLa and MSU-1.1 cells resulted in increased
sensitivity to cisplatin [44, 45]. Further support for
the role of DNA Pol ζ in tolerance to crosslinks
comes from the observation that knockouts for
REV3L are hypersensitive to fotemustine, a crosslink-
ing agent that has been used for therapy of malignant
melanomas [46].
We found that levels of DNA Pol ζ were increased
after cisplatin treatment by 2- to 10-fold in all three
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melanoma cell lines tested, but no increase was seen in
ovarian cancer cells and fibroblasts. There was also an
increase in DNA Pol η, but this was not melanoma-
specific. The significance of the DNA Pol ζ result to the
melanoma RAD51 response was demonstrated when we
knocked down DNA Pol ζ levels and observed signifi-
cantly slower growth and increased apoptosis after
cisplatin treatment compared to the scrambled siRNA
control during the three day time course of our assay.
We have chosen to demonstrate the survival benefit to
melanoma cells of their RAD51 response to cisplatin in
a combination of short term growth, cell cycle analysis
and apoptosis assays rather than conventional colony
formation assays because we consider it more closely
represents the in vivo situation. Patients typically receive
platinum-based chemotherapy as a single intravenous in-
fusion at three weekly intervals, with the maximum
plasma concentration of free cisplatin in the range
1–5 μM decreasing rapidly with a half-life of less than
1 h [47], so therapeutic concentrations will only persist
for less than 1 day at a time. Our assays, using cisplatin
concentrations within the physiological range, show that
the novel response, whereby levels of RAD51 are dra-
matically reduced, allows melanoma cells to survive and
continue to grow under these conditions and that the
compensatory increase in levels of DNA Pol ζ is an im-
portant part of this response. However, it is important to
remember that, despite the RAD51 response, melanoma
cells are under considerable stress during the exposure
to these high concentrations of cisplatin and are growing
more slowly with higher levels of apoptosis than
untreated cultures and would likely not survive the non-
physiological continuous cisplatin exposures needed for
colony formation assays.
Conclusion
We have shown that, rather than boosting levels of
RAD51 on treatment with cisplatin, in a possibly unsuc-
cessful attempt to repair high levels of ICLs encountered
at stalled replication forks by the protracted HRR
process, melanoma cells instead shut down HRR and
boost levels of endonucleases, such as ERCC1-XPF, that
can rapidly unhook crosslinks encountered prior to, and
possibly also during replication but before replication
fork arrest, and then use translesion synthesis DNA
polymerases to allow replication to proceed. In addition,
elevated levels of endonucleases and translesion synthe-
sis DNA polymerases can be used to boost post-
replication repair of ICLs bypassed by replication
traverse. This approach of DNA damage tolerance rather
than immediate repair may be a more appropriate strat-
egy for an aggressive and rapidly growing tumour like
melanoma, that also enables it to better survive exposure
to platinum chemotherapeutics. However, this strategy
could also result in melanoma exposing an Achilles heel,
a BRCAness phenotype rendering it more susceptible to
PARP inhibitor therapy.
Additional file
Additional file 1: Figure S1. Western blots showing that the reduction
in RAD51 levels after cisplatin treatment in melanoma cells is not seen in
other cell types. Blots support the RAD51 quantification shown in Fig. 2
of the main text. Figure S2. Images showing that RAD51 repair foci are
not induced by short term cisplatin treatment of melanoma cells. Figure
S3. The cisplatin-induced reduction in RAD51 levels in melanoma cells is
not affected by proteasome or lysosome inhibitor treatment.
Figure S4. Melanoma cells show only a weak cisplatin-induced G2 arrest.
Figure S5. Specificity of antibodies to translesion synthesis DNA Polymer-
ases. Figure S6. Western blots showing increased levels of DNA Poly-
merase zeta in cisplatin-treated melanoma cells. Blots support the DNA
Pol ζ and Pol η expression data shown in Fig. 7 of the main text. (PDF
2393 kb)
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